Anolik Robert
Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):683-94. doi: 10.1517/17425250902980187.
Allergic rhinitis (AR) is rapidly increasing in global prevalence. Symptoms of AR, particularly nasal congestion, can cause quality of life (QoL) impairment. Second-generation antihistamines are a recommended first-line therapy for AR but are not viewed as very effective for the treatment of congestion. Therefore, an antihistamine plus a decongestant, such as the combination of desloratadine and pseudoephedrine, is a convenient and efficacious treatment.
To review the clinical evidence on the efficacy and safety of combination desloratadine/pseudoephedrine for the treatment of AR symptoms, particularly nasal congestion.
Four large studies found that improvement in nasal congestion is enhanced when patients are treated with combination desloratadine/pseudoephedrine. The combination drug significantly improved mean reflective nasal congestion scores in these studies compared with either component as monotherapy (p <or= .009 for all). These improvements in congestion were observed by day 2. Mean reductions in nasal congestion scores were comparable between the once- and twice-daily dosing regimens of the combination drug.
Comprehensive treatment of AR that effectively relieves nasal congestion can also improve patient QoL. Administration of the second-generation antihistamine desloratadine in combination with the decongestant pseudoephedrine may be regarded as an efficacious and convenient option for patients with AR who are particularly troubled by nasal congestion.
过敏性鼻炎(AR)的全球患病率正在迅速上升。AR的症状,尤其是鼻塞,会导致生活质量(QoL)受损。第二代抗组胺药是推荐用于AR的一线治疗药物,但对于鼻塞的治疗效果并不被认为非常有效。因此,抗组胺药加减充血剂,如地氯雷他定和伪麻黄碱的组合,是一种方便且有效的治疗方法。
综述地氯雷他定/伪麻黄碱联合治疗AR症状,尤其是鼻塞的疗效和安全性的临床证据。
四项大型研究发现,患者使用地氯雷他定/伪麻黄碱联合治疗时,鼻塞的改善情况会增强。在这些研究中,与单一使用任何一种成分相比,联合药物显著改善了平均反射性鼻塞评分(所有比较的p≤0.009)。在第2天就观察到了鼻塞的这些改善。联合药物的每日一次和每日两次给药方案在鼻塞评分的平均降低方面相当。
有效缓解鼻塞的AR综合治疗也可以改善患者的生活质量。对于特别受鼻塞困扰的AR患者,第二代抗组胺药地氯雷他定与减充血剂伪麻黄碱联合给药可被视为一种有效且方便的选择。